Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dx at heart of high-profile NHS drug approval

This article was originally published in Clinica

Executive Summary

It is extremely rare that a high-profile approval of a pharmaceutical for NHS use is as dependent on diagnostic testing and monitoring as that of Herceptin, as recommended today by the National Institute for Health and Clinical Excellence (NICE). According to the draft guidance, the use of trastuzumab for early HER2-positive breast cancer will be subject to tight cardiac function parameters that are to be assessed prior to treatment, and then every three months.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel